乳腺导管原位癌腋窝评估:临床实践指南诊断准确性受质疑
该研究将8部关于导管原位癌(DCIS) upfront 前哨淋巴结活检(SLND)的临床实践指南应用于SentiNot前瞻性研究患者,由6名独立盲法评估者解读。结果显示观察者间一致性差异大(kappa 0.23-0.9),指南诊断准确性低(AUC 0.45-0.55),50-90%的纯DCIS患者接受不必要SLNB,而10-50%的浸润癌未被识别为高危。结论认为现有指南无法准确识别可从upfront SLNB获益的DCIS患者。
要点
- 现有DCIS腋窝评估指南解读一致性差,诊断准确性低(AUC 0.45-0.55)。
- 按指南操作可致50-90%纯DCIS患者过度SLNB,且10-50%浸润癌漏判高危。
- 指南间一致性低(kappa=0.24),需细化术前评估和SLND识别新技术。
核心结论
- 现有临床实践指南无法准确识别可从upfront前哨淋巴结活检获益的DCIS患者,需修订指南并开发新技术以避免过度治疗。
研究设计与样本
- 研究识别了8部关于DCIS upfront SLND的临床实践指南,并应用于前瞻性SentiNot研究中的患者。
- 患者由6名独立、盲法评估者进行评估,采用一致性统计和ROC曲线评估指南准确性。
主要发现
- 观察者间一致性差异大(kappa:0.23-0.9),是否应行SLND的解读范围为40-90%,一致性为32-88%。
- 指南诊断准确性低,AUC范围为0.45-0.55。
- 50-90%的纯DCIS患者会接受不必要的SLNB,而10-50%的浸润癌患者未被识别为「高危」。
- 指南间一致性低(kappa=0.24),不同患者被不准确治疗的风险相似。
关键数值与推荐
- 指南推荐在后续SLN检测预计困难或浸润风险高时行upfront SLND。
- 指南间推荐不一致,导致实践差异大。
临床怎么用
- 临床决策需谨慎解读现有指南,避免仅依据指南对DCIS患者常规行upfront SLNB。
- 应结合详细术前评估和新型SLND识别技术来优化腋窝评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Staging of the axilla is not routine in ductal cancer in situ (DCIS) although invasive cancer is observed in 20-25 per cent of patients at final pathology. Upfront sentinel lymph node dissection (SLND) is advocated in clinical practice guidelines in certain situations. These include expected challenges in subsequent SLN detection and when the risk for invasion is high. Clinical practice guidelines are, however, inconsistent and lead to considerable practice variability. METHODS: Clinical practice guidelines for upfront SLND in DCIS were identified and applied to patients included in the prospective SentiNot study. These patients were evaluated by six independent, blinded raters. Agreement statistics were performed to assess agreement and concordance. Receiver operating characteristic curves were constructed, to assess guideline accuracy in identifying patients with underlying invasion. RESULTS: Eight guidelines with relevant recommendations were identified. Interobserver agreement varied greatly (kappa: 0.23-0.9) and the interpretation as to whether SLND should be performed ranged from 40-90 per cent and with varying concordance (32-88 per cent). The diagnostic accuracy was low with area under the curve ranging from 0.45 to 0.55. Fifty to 90 per cent of patients with pure DCIS would undergo unnecessary SLNB, whereas 10-50 per cent of patients with invasion were not identified as 'high risk'. Agreement across guidelines was low (kappa = 0.24), meaning that different patients had a similar risk of being treated inaccurately. CONCLUSION: Available guidelines are inaccurate in identifying patients with DCIS who would benefit from upfront SLNB. Guideline refinement with detailed preoperative work-up and novel techniques for SLND identification could address this challenge and avoid overtreatment. LAY SUMMARY: The decision whether to operate on the axilla in women with a diagnosis of ductal cancer in situ (DCIS) is based on the risk of an undiagnosed underlying invasive cancer and on the concern that resection of the breast will not allow for accurate axillary mapping afterwards. Guidelines stem from older knowledge and are heterogeneous. In this study, different breast cancer guidelines were tested in a patient cohort from the SentiNot prospective trial for uniformity of interpretation and diagnostic accuracy. Results show that guidelines did not allow for easy and uniform interpretation and had the predictive ability of the toss of a coin. This suggests that guidelines regarding the need of axillary evaluation in patients operated for DCIS need to be revised and that techniques that will address the conundrum should be developed. The decision whether to operate on the axilla in women with a diagnosis of ductal cancer in situ (DCIS) is based on the risk of an undiagnosed underlying invasive cancer and on the concern that resection of the breast will not allow for accurate axillary mapping afterwards. Guidelines stem from older knowledge and are heterogeneous. In this study, different breast cancer guidelines were tested in a patient cohort from the SentiNot prospective trial for uniformity of interpretation and diagnostic accuracy. Results show that guidelines did not allow for easy and uniform interpretation and had the predictive ability of the toss of a coin. This suggests that guidelines regarding the need of axillary evaluation in patients operated for DCIS need to be revised and that techniques that will address the conundrum should be developed.
引用
- Karakatsanis A, Charalampoudis P, Pistioli L, et al. Axillary evaluation in ductal cancer in situ of the breast: challenging the diagnostic accuracy of clinical practice guidelines. Br J Surg. 2021. PMID: 34089583. doi:10.1093/bjs/znab149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。